
|Videos|May 20, 2021
The Ever-Expanding Multiple Sclerosis Therapeutics
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Suma Shah, MD
Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine - S. Mitchell Freedman, MD FAAN
Adjunct Professor of Neurology, University of North Carolina-Chapel Hill
Key Learning Objectives
- Virtual patient visits during COVID-19 when treating MS
- Changing barriers to treating MS
- Evolution of monitoring safety and efficacy of therapy
- The future of treating MS
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
2
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
3
Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease
4
Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)
5








































